Matinas BioPharma Investor Presentation Deck

12 MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options • 14 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nationwide Children's Hospital, Vanderbilt University Medical Center, Children's Hospital of Philadelphia • Patients were not responding/resistant to, or unable to receive, azole therapy • Patients were switched to treatment with IV Amphotericin B with clinical response but unable to tolerate treatment due renal toxicity All patients hospitalized to monitor/manage renal safety and most received IV electrolyte supplementation Following oral MAT2203 initiation, patients were discharged to continue treatment at home Renal toxicity reversed and renal function returned to baseline • All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients ● COPYRIGHT MATINAS BIOPHARMA 2024 MATINAS BIOPHARMA

View entire presentation